125 related articles for article (PubMed ID: 28928162)
1. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
2. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Chevreau C; Massard C; Flechon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Fizazi K; Mourey L; Paci A; Guitton J; Thomas F; Lelièvre B; Ciccolini J; Moeung S; Gallois Y; Olivier P; Culine S; Filleron T; Chatelut E
Cancer Med; 2021 Apr; 10(7):2250-2258. PubMed ID: 33675184
[TBL] [Abstract][Full Text] [Related]
3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Moeung S; Chevreau C; Marsili S; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Filleron T; Delmas C; Lafont T; Chatelut E; Thomas F
Pharm Res; 2020 Jul; 37(7):147. PubMed ID: 32676789
[TBL] [Abstract][Full Text] [Related]
5. Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.
Kloft C; Siegert W; Jaehde U
Br J Cancer; 2003 Sep; 89(5):787-94. PubMed ID: 12942106
[TBL] [Abstract][Full Text] [Related]
6. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.
Thomas F; Séronie-Vivien S; Gladieff L; Dalenc F; Durrand V; Malard L; Lafont T; Poublanc M; Bugat R; Chatelut E
Clin Pharmacokinet; 2005; 44(12):1305-16. PubMed ID: 16372828
[TBL] [Abstract][Full Text] [Related]
7. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
8. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
10. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
13. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
Johansen MJ; Madden T; Mehra RC; Wood JG; Rondon G; Browne V; Newman RA; Champlin RE
J Clin Oncol; 1997 Apr; 15(4):1481-91. PubMed ID: 9193344
[TBL] [Abstract][Full Text] [Related]
15. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.
Patoux A; Bleyzac N; Boddy AV; Doz F; Rubie H; Bastian G; Maire P; Canal P; Chatelut E
Eur J Clin Pharmacol; 2001 Jul; 57(4):297-303. PubMed ID: 11549207
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.
Feldman DR; Glezerman I; Patil S; Van Alstine L; Bajorin DF; Fischer P; Hughes A; Sheinfeld J; Bains M; Reich L; Woo K; Giralt S; Bosl GJ; Motzer RJ
Clin Genitourin Cancer; 2015 Oct; 13(5):453-60. PubMed ID: 26072101
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
18. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Motzer RJ; Mazumdar M; Sheinfeld J; Bajorin DF; Macapinlac HA; Bains M; Reich L; Flombaum C; Mariani T; Tong WP; Bosl GJ
J Clin Oncol; 2000 Mar; 18(6):1173-80. PubMed ID: 10715285
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
20. Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.
Merino-Sanjuán M; Monteiro JF; Porta-Oltra B; Maestu I; Almenar D; Jiménez-Torres NV
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):457-64. PubMed ID: 21726412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
